Holdings
Biotechnology Fund
As of Jun 30, 2026, Biotechnology Fund reported 67 positions worth US$134M. Largest: Abbvie Inc., Amgen Inc. and Gilead Sciences, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Abbvie Inc. | 44,415 | US$11.2M | −1,508 | Jun 30, 2026 |
| Amgen Inc. | 19,065 | US$6.9M | −1,028 | Jun 30, 2026 |
| Gilead Sciences, Inc. | 48,654 | US$6.15M | +612 | Jun 30, 2026 |
| Vertex Pharmaceuticals Incorporated | 11,897 | US$5.91M | −222 | Jun 30, 2026 |
| Regeneron Pharmaceuticals, Inc. | 6,432 | US$4.01M | +208 | Jun 30, 2026 |
| Revolution Medicines, Inc. | 18,109 | US$3.39M | −5,366 | Jun 30, 2026 |
| Alnylam Pharmaceuticals, Inc. | 10,721 | US$3.23M | +89 | Jun 30, 2026 |
| Beone Medicines Ltd. Class A | 10,427 | US$2.97M | +32 | Jun 30, 2026 |
| Moderna, Inc. | 41,976 | US$2.94M | −1,842 | Jun 30, 2026 |
| Biogen Inc. | 13,465 | US$2.91M | −1,338 | Jun 30, 2026 |